LivaNova (LIVN) Stock Price, News & Analysis

Company Overview

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications. In neuromodulation, LivaNova offers VNS Therapy, an implantable system that uses electrical stimulation of the vagus nerve as an adjunctive treatment for drug-resistant epilepsy and treatment-resistant depression in eligible patients.

LivaNova was created in 2015 through the merger of Cyberonics, a U.S. neuromodulation company, and Sorin, an Italian cardiovascular device business. The company serves hospitals, clinicians and patients in the United States and international markets, with products distributed across regions including Europe and other markets worldwide. Damien McDonald has served as LivaNova’s chief executive officer since 2018.

Key Stats

• Today's Range: $76.20 to $79.11
• 50-Day Range: $74.70 to $82.40
• 52-Week Range: $48.82 to $85.76
• Volume: 737,976 shs
• Average Volume: 673,097 shs
• Market Capitalization: $4.32 billion
• P/E Ratio: 21.19
• Dividend Yield: N/A
• Price Target: $87.75
• Consensus Rating: Moderate Buy

LivaNova Stock Analysis - MarketRank™

LivaNova scored higher than 60% of companies evaluated by MarketBeat, and ranked 298th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LivaNova has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

LivaNova has a consensus price target of $87.75, representing about 11.8% upside from its current price of $78.50.

Amount of Analyst Coverage

LivaNova has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.05%

Earnings Growth

Earnings for LivaNova are expected to grow by 10.05% in the coming year, from $3.78 to $4.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LivaNova is 21.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 35.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of LivaNova is 21.19, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 206.61.

Price to Book Value per Share Ratio

LivaNova has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.93% of the float of LivaNova has been sold short.

Short Interest Ratio / Days to Cover

LivaNova has a short interest ratio ("days to cover") of 8.04.

Change versus previous month

Short interest in LivaNova has recently increased by 11.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LivaNova does not currently pay a dividend.

Dividend Growth

LivaNova does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.80

News Sentiment

LivaNova has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for LivaNova this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LivaNova insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $591,839.00 in company stock.

Percentage Held by Insiders

0.35% of the stock of LivaNova is held by insiders.

Percentage Held by Institutions

97.64% of the stock of LivaNova is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:LIVN
• CIK: 1639691
• Web: www.livanova.com
• Phone: 442033250660
• Fax: 281-218-9332
• Employees: 3,300
• Year Founded: 2015

Price Target and Rating

• Average Price Target for LivaNova: $87.75
• High Price Target: $105.00
• Low Price Target: $66.00
• Potential Upside/Downside: +11.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.38
• Trailing P/E Ratio: 21.19
• Forward P/E Ratio: 20.77
• P/E Growth: N/A
• Net Income: -$242.47 million
• Net Margins: 12.82%
• Pretax Margin: 7.31%
• Return on Equity: 16.35%
• Return on Assets: 7.76%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 1.45
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $1.39 billion
• Price / Sales: 3.12
• Cash Flow: $4.99 per share
• Price / Cash Flow: 15.73
• Book Value: $21.98 per share
• Price / Book: 3.57

Miscellaneous

• Outstanding Shares: 55,090,000
• Free Float: 54,901,000
• Market Cap: $4.32 billion
• Optionable: Optionable
• Beta: 0.87